A Study to See if Certain Antioxidants and Vitamins Will Keep Lactate Levels Down in Patients Taking Anti-HIV Drugs
A Pilot Study of the Efficacy of a Combination of Antioxidants and B Vitamins in Preventing the Recurrence of Hyperlactatemia in Subjects Who Have Limited Antiretroviral Options
2 other identifiers
interventional
N/A
1 country
4
Brief Summary
The purpose of this study is to see if certain vitamins (C, E, B1, and B2) can keep lactate levels from becoming too high in patients who are taking nucleoside reverse transcriptase inhibitor (NRTI) anti-HIV drugs. Some patients taking anti-HIV drugs develop hyperlactatemia. Hyperlactatemia is a condition in which lactate (a natural substance normally present in the body) levels are too high. Too much lactate in the body can lead to serious health problems. When patients suffer from hyperlactatemia while taking anti-HIV drugs, most doctors temporarily stop the drugs. Patients then restart the anti-HIV drugs when their lactate levels return to normal. If patients restart the same drugs they were taking when they developed hyperlactatemia, there is a risk that they may develop high lactate levels again. This study wants to find out if taking antioxidants (substances that reduce tissue damage due to oxygen radicals) and certain B vitamins may help prevent patients from developing hyperlactatemia when they restart the same anti-HIV drugs.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 14, 2002
CompletedFirst Posted
Study publicly available on registry
May 15, 2002
CompletedJune 4, 2015
June 1, 2003
May 14, 2002
June 3, 2015
Conditions
Keywords
Interventions
Eligibility Criteria
You may qualify if:
- Patients may be eligible for this study if they:
- Are at least 13 years old.
- Are HIV infected.
- Agree not to become pregnant or to impregnate during the study. The study volunteer/partner must use acceptable methods of contraception while receiving the study drugs and for 1 month after stopping the study drugs. Men and women who cannot have children do not need to use contraception.
- Have had their first episode of serious hyperlactatemia (including lactic acidosis) within 180 days prior to study entry. Serious hyperlactatemia must have led to discontinuation of all anti-HIV drugs.
- Have limited anti-HIV drug choices because of prior intolerance to anti-HIV drugs or virologic failure.
- Are willing and able to restart the same anti-HIV regimen that led to the episode of serious hyperlactatemia.
- Have complete resolution or return to baseline of all the signs and symptoms thought to be related to the episode of hyperlactatemia.
You may not qualify if:
- Patients may not be eligible for this study if they:
- Were on an abacavir-containing regimen for less than 6 weeks at the time of the hyperlactatemia episode or had a fever or rash during the episode of hyperlactatemia, regardless of the length of time on abacavir.
- Are pregnant or breast-feeding.
- Have any medical condition or drug use that could have, by itself, resulted in hyperlactatemia.
- Were diagnosed with pancreatitis at the time of the hyperlactatemia episode.
- Are allergic/sensitive to vitamin C, E, B1, and/or B2.
- Use systemic cytotoxic chemotherapy.
- Actively use or are dependent on alcohol or drugs in a way that would affect the protocol.
- Had a short but intense illness within 30 days before entry that would interfere with participation in the study.
- Require or are unwilling to discontinue certain drugs.
- Have any condition that would affect their ability to participate in the study.
- Are taking vitamin supplements that include more that 200 percent of the Recommended Daily Allowance (RDA) of any of the study drugs and are unwilling to stop taking the supplements or substitute them with supplements that contain 200 percent or less than the RDA of the study drugs.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (4)
Univ of Colorado Health Sciences Ctr
Denver, Colorado, 80262, United States
Case Western Reserve Univ
Cleveland, Ohio, 44106, United States
MetroHealth Med Ctr
Cleveland, Ohio, 441091998, United States
Univ of Pennsylvania, Philadelphia
Philadelphia, Pennsylvania, 19104, United States
Related Publications (3)
Brinkman K, Vrouenraets S, Kauffmann R, Weigel H, Frissen J. Treatment of nucleoside reverse transcriptase inhibitor-induced lactic acidosis. AIDS. 2000 Dec 1;14(17):2801-2. doi: 10.1097/00002030-200012010-00027. No abstract available.
PMID: 11125906BACKGROUNDBrinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet. 1999 Sep 25;354(9184):1112-5. doi: 10.1016/S0140-6736(99)06102-4.
PMID: 10509516BACKGROUNDBrinkman K, Kakuda TN. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy? Curr Opin Infect Dis. 2000 Feb;13(1):5-11. doi: 10.1097/00001432-200002000-00002.
PMID: 11964766BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Grace McComsey
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Purpose
- PREVENTION
- Sponsor Type
- NIH
Study Record Dates
First Submitted
May 14, 2002
First Posted
May 15, 2002
Last Updated
June 4, 2015
Record last verified: 2003-06